Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 445

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 445
---
 medical insurance in 2023 and 2024 was paid by Cerevast. |

Outstanding Equity Awards as of 2024 Fiscal Year-End

The following table provides a summary of stock option awards outstanding as of December 31, 2024 for the named executive officers. No named executive officer had any unvested restricted stock awards as of December 31, 2024.

|          |     | Option             
 Awards             
 Number             
 of Securities      
 Underlying Options 
 Exercisable        |         |    |     | Number             
 of Securities      
 Underlying Options 
 Unexercisable      |   |     | Option   
 Exercise 
 Price    |    |   |     | Option     
 Expiration 
 Date       |    |   |
|:---------|:----|:-------------------|--------:|---:|:----|:-------------------|:--|:----|:---------|:---|:--|:----|:-----------|:---|:--|
| Bradford 
 A. Zakes |     |                    | 350,000 | -1 |     |                    | — |     | $        | (1 | ) |     |            | (1 | ) |
| Brenda   
 Sparks   |     |                    |       — |    |     |                    | — |     |          | —  |   |     |            | —  |   |

| (1) | Reflects                                                                                                                                
 300,000 vested options to acquire Cerevast common stock expiring July 30, 2025 and 50,000 vested options to acquire Cerevast common     
 stock expiring July 2, 2025. Each of such options is exercisable at an exercise price of $0.0001 per share and will, in connection      
 with the Business Combination, convert into options to acquire an aggregate of 576,342 shares of FutureTech Common Stock at an exercise 
 price of $0.01 per share.                                                                                                               |

Additional Narrative Disclosure Existing Employment Agreement Bradford A. Zakes

Mr. Zakes entered into an Executive Employment Agreement with Longevity dated December 27, 2022

that provides for his employment as Longevity’s Chief Executive Officer effective as of the Closing. The agreement provides that Mr. Zakes will receive an annual base salary of $450,000, which may be increased or decreased as may be approved by Longevity’s board of directors. Mr. Zakes is also entitled to receive a discretionary